Principal Financial Group Inc. Grows Position in Boston Scientific Co. (NYSE:BSX)

Principal Financial Group Inc. grew its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 5.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,010,441 shares of the medical equipment provider's stock after purchasing an additional 111,724 shares during the period. Principal Financial Group Inc. owned approximately 0.14% of Boston Scientific worth $168,475,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. CRA Financial Services LLC raised its stake in shares of Boston Scientific by 4.3% in the 3rd quarter. CRA Financial Services LLC now owns 2,841 shares of the medical equipment provider's stock worth $238,000 after buying an additional 117 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in Boston Scientific by 9.7% during the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,352 shares of the medical equipment provider's stock valued at $115,000 after buying an additional 119 shares in the last quarter. CVA Family Office LLC raised its position in Boston Scientific by 7.4% during the second quarter. CVA Family Office LLC now owns 1,909 shares of the medical equipment provider's stock valued at $147,000 after buying an additional 131 shares during the period. Jacobsen Capital Management raised its holdings in shares of Boston Scientific by 4.9% during the third quarter. Jacobsen Capital Management now owns 2,820 shares of the medical equipment provider's stock worth $236,000 after acquiring an additional 133 shares in the last quarter. Finally, S.A. Mason LLC boosted its stake in shares of Boston Scientific by 6.1% during the 3rd quarter. S.A. Mason LLC now owns 2,335 shares of the medical equipment provider's stock worth $196,000 after acquiring an additional 135 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Analysts Set New Price Targets

BSX has been the topic of several recent research reports. Barclays lifted their price objective on Boston Scientific from $78.00 to $86.00 and gave the stock an "overweight" rating in a report on Thursday, August 22nd. Needham & Company LLC reiterated a "hold" rating on shares of Boston Scientific in a research report on Thursday, October 31st. Raymond James raised their price objective on shares of Boston Scientific from $91.00 to $94.00 and gave the stock a "strong-buy" rating in a report on Wednesday, September 4th. Robert W. Baird increased their target price on Boston Scientific from $90.00 to $91.00 and gave the stock an "outperform" rating in a report on Thursday, July 25th. Finally, Mizuho lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $93.39.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $1.45 during trading on Friday, reaching $88.33. 3,309,355 shares of the company traded hands, compared to its average volume of 6,081,630. Boston Scientific Co. has a 52-week low of $50.84 and a 52-week high of $88.94. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The firm has a 50 day simple moving average of $84.35 and a 200-day simple moving average of $78.74. The stock has a market capitalization of $130.18 billion, a PE ratio of 71.82, a P/E/G ratio of 2.50 and a beta of 0.79.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.59 by $0.04. The firm had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company's revenue for the quarter was up 19.3% on a year-over-year basis. During the same period last year, the business posted $0.50 EPS. Equities research analysts anticipate that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total transaction of $570,511.10. Following the transaction, the executive vice president now owns 37,468 shares of the company's stock, valued at $3,061,135.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the transaction, the executive vice president now directly owns 160,467 shares of the company's stock, valued at approximately $13,639,695. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total value of $570,511.10. Following the transaction, the executive vice president now owns 37,468 shares of the company's stock, valued at $3,061,135.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 309,270 shares of company stock worth $26,196,718 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.